Cell Transplantation最新文献_第2页

Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial.

IF 3.2 4区医学

Cell Transplantation Pub Date : 2025-01-01 DOI: 10.1177/09636897241303275

Bong-Woo Lee, Jennifer Jooha Lee, Joon-Yong Jung, Ji Hyeon Ju

{"title":"Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial.","authors":"Bong-Woo Lee, Jennifer Jooha Lee, Joon-Yong Jung, Ji Hyeon Ju","doi":"10.1177/09636897241303275","DOIUrl":"10.1177/09636897241303275","url":null,"abstract":"To assess the impact of a single intra-articular (IA) injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with knee osteoarthritis (OA), a randomized, double-blind, placebo-controlled study was conducted. The study included 24 patients with knee OA who were randomly assigned to receive either a single IA injection of BM-MSCs or normal saline. Changes in the visual analog scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Knee Injury and Osteoarthritis Outcome Score (KOOS) after IA injection were assessed at 3, 6, 9, and 12 months. Magnetic resonance imaging (MRI) with T2 mapping sequences was conducted for knee cartilage assessment at baseline and at 3 and 12 months. The MSC group showed between-group improvement in WOMAC (-5.0 ± 3.6 vs. -0.1 ± 5.5, P = 0.02) and KOOS (23.9 ± 18.3 vs. 7.2 ± 15.9, P = 0.028) scores at 9 months compared with the control group. The MSC group exhibited a less sharp increase in the mean T2 value of the medial compartment than the control group at 12 months, with no serious adverse events observed during follow-up. A single IA injection of allogeneic BM-MSCs provided satisfactory pain relief for patients with knee OA compared with the control group at 9 months. Quantitative T2 MRI mapping of the cartilage showed that IA BM-MSCs could have a preventive effect on OA progression for 12 months. Our findings suggest the potential of allogeneic BM-MSCs IA injection as a pain-relieving and disease-modifying treatment for patients with knee OA in the outpatient setting.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"34 ","pages":"9636897241303275"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the Development and Application of Human Organoids: Techniques, Applications, and Future Perspectives.

IF 3.2 4区医学

Cell Transplantation Pub Date : 2025-01-01 DOI: 10.1177/09636897241303271

Zhangcheng Zhu, Yiwen Cheng, Xia Liu, Wenwen Ding, Jiaming Liu, Zongxin Ling, Lingbin Wu

{"title":"Advances in the Development and Application of Human Organoids: Techniques, Applications, and Future Perspectives.","authors":"Zhangcheng Zhu, Yiwen Cheng, Xia Liu, Wenwen Ding, Jiaming Liu, Zongxin Ling, Lingbin Wu","doi":"10.1177/09636897241303271","DOIUrl":"10.1177/09636897241303271","url":null,"abstract":"Organoids are three-dimensional (3D) cell cultures derived from human pluripotent stem cells or adult stem cells that recapitulate the cellular heterogeneity, structure, and function of human organs. These microstructures are invaluable for biomedical research due to their ability to closely mimic the complexity of native tissues while retaining human genetic material. This fidelity to native organ systems positions organoids as a powerful tool for advancing our understanding of human biology and for enhancing preclinical drug testing. Recent advancements have led to the successful development of a variety of organoid types, reflecting a broad range of human organs and tissues. This progress has expanded their application across several domains, including regenerative medicine, where organoids offer potential for tissue replacement and repair; disease modeling, which allows for the study of disease mechanisms and progression in a controlled environment; drug discovery and evaluation, where organoids provide a more accurate platform for testing drug efficacy and safety; and microecological research, where they contribute to understanding the interactions between microbes and host tissues. This review provides a comprehensive overview of the historical development of organoid technology, highlights the key achievements and ongoing challenges in the field, and discusses the current and emerging applications of organoids in both laboratory research and clinical practice.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"34 ","pages":"9636897241303271"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can Islet Transplantation Possibly Reduce Mortality in Type 1 Diabetes. 胰岛移植能降低1型糖尿病患者的死亡率吗？

IF 3.2 4区医学

Cell Transplantation Pub Date : 2025-01-01 DOI: 10.1177/09636897241312801

Jeffrey S Isenberg, Fouad Kandeel

引用次数: 0

The Potential of Neonatal Organ Donation in Central Sweden.

IF 3.2 4区医学

Cell Transplantation Pub Date : 2025-01-01 DOI: 10.1177/09636897241303269

Emil Bluhme, Ewa Henckel, Boubou Hallberg, Carl Jorns

{"title":"The Potential of Neonatal Organ Donation in Central Sweden.","authors":"Emil Bluhme, Ewa Henckel, Boubou Hallberg, Carl Jorns","doi":"10.1177/09636897241303269","DOIUrl":"10.1177/09636897241303269","url":null,"abstract":"Pediatric organ transplant recipients have a higher risk for wait list mortality due to the scarcity of size matched organs. Neonatal organ donation could potentially ameliorate the discrepancy but is currently not implemented in Sweden. This study aims to evaluate the potential of neonatal organ donation in central Sweden using a standardized protocol with organ specific criteria. Data on 2,061 neonates who deceased in central Sweden from 2006 to 2016 were collected; 308 neonates met criteria for possible donation. Medical records of all possible donors were reviewed, identifying 85 potential donors. Main cause of death was hypoxic ischemic encephalopathy 47% (n = 40). Median weight was 2,355 (IQR: 1,953) g, with 31% receiving inotropic support. Median creatinine of 72 (IQR: 67) µmol/l, urine production 3 (IQR: 2.2) ml/kg/h, ALT 0.51 (IQR: 1.5) µkat/l, and AST 1.7 (IQR: 3.1) µkat/l. Criteria for kidney donation was met in 39 potential neonatal, 29 for liver and 18 for heart, corresponding to a potential increase of 1.9, 1.4, and 0.9 donors PMP per year, respectively. In total, 16 neonates had a catastrophic neurological injury in combination with lack of brainstem reflexes, indicating plausibility of donation after brain death. Expanding organ donation into the neonatal period in Sweden could lead to an increase in organs available for transplant.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"34 ","pages":"9636897241303269"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation.

IF 3.2 4区医学

Cell Transplantation Pub Date : 2025-01-01 DOI: 10.1177/09636897241303292

Xiaoping Li, Yu Li, Dingsong Zhang, Xiaozhuang Hu, Lin Liu, Zhongtao Yuan, Shiqi Li, Yancheng Dong, Yingnian Chen, Sanbin Wang

{"title":"The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation.","authors":"Xiaoping Li, Yu Li, Dingsong Zhang, Xiaozhuang Hu, Lin Liu, Zhongtao Yuan, Shiqi Li, Yancheng Dong, Yingnian Chen, Sanbin Wang","doi":"10.1177/09636897241303292","DOIUrl":"10.1177/09636897241303292","url":null,"abstract":"Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high. In this study, we retrospectively analyzed the data of 11 DSA-positive patients who received haplo-HSCT at our center and evaluated the therapeutic efficacy of the combination of intravenous immunoglobulin (IVIG), dexamethasone and high dose of transfused mononuclear cells (MNCs) for DSA desensitization. The kinetics of DSAs at different times and the engraftment and transplantation outcomes were also observed. We found that all patients had successful donor-cell engraftment and that no patient developed poor graft function. The median engraftment times of neutrophils and platelets were 14 days (range, 11-24 days) and 13 days (range, 11-123 days), respectively. The DSA levels of all patients became negative or dropped under 2000 within 22 days after HSCT. A total of 36.4% of patients developed grade II-IV acute graft-versus-host disease (aGVHD), and 9.1% of patients died of severe gastrointestinal aGVHD. Of the 7 surviving patients, four were diagnosed with chronic GVHD. After a median follow-up of 28.9 months (2.0-52.1 months), four patients died: of relapse (two), aGVHD (one), and multiple-organ failure (one). The 2-year OS, DFS, and NRM were 63.6%, 45.4%, and 18.2%, respectively. Combination therapy with IVIG, dexamethasone, and a high dose of MNCs transfusion, a simple and efficient procedure, was safe and effective for DSA desensitization and peripheral blood stem cell (PBSC) engraftment.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"34 ","pages":"9636897241303292"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143051812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Development of Mesenchymal Stem Cell-Derived Extracellular Vesicles.

IF 3.2 4区医学

Cell Transplantation Pub Date : 2025-01-01 DOI: 10.1177/09636897241297623

Bingyi Zheng, Xueting Wang, Meizhai Guo, Chi-Meng Tzeng

引用次数: 0

ASNTR 2024 Abstracts ASNTR 2024 摘要

IF 3.3 4区医学

Cell Transplantation Pub Date : 2024-05-23 DOI: 10.1177/09636897241250096

引用次数: 0

Role of Hedgehog Signaling Pathways in Multipotent Mesenchymal Stem Cells Differentiation 刺猬信号通路在多能间质干细胞分化中的作用

IF 3.3 4区医学

Cell Transplantation Pub Date : 2024-05-02 DOI: 10.1177/09636897241244943

Mengyu Wu, Junwei Mi, Guo-xin Qu, Shu Zhang, Yi Jian, Chu Gao, Qingli Cai, Jing Liu, Jianxin Jiang, Hong Huang

{"title":"Role of Hedgehog Signaling Pathways in Multipotent Mesenchymal Stem Cells Differentiation","authors":"Mengyu Wu, Junwei Mi, Guo-xin Qu, Shu Zhang, Yi Jian, Chu Gao, Qingli Cai, Jing Liu, Jianxin Jiang, Hong Huang","doi":"10.1177/09636897241244943","DOIUrl":"https://doi.org/10.1177/09636897241244943","url":null,"abstract":"Multipotent mesenchymal stem cells (MSCs) have high self-renewal and multi-lineage differentiation potentials and low immunogenicity, so they have attracted much attention in the field of regenerative medicine and have a promising clinical application. MSCs originate from the mesoderm and can differentiate not only into osteoblasts, cartilage, adipocytes, and muscle cells but also into ectodermal and endodermal cell lineages across embryonic layers. To design cell therapy for replacement of damaged tissues, it is essential to understand the signaling pathways, which have a major impact on MSC differentiation, as this will help to integrate the signaling inputs to initiate a specific lineage. Hedgehog (Hh) signaling plays a vital role in the development of various tissues and organs in the embryo. As a morphogen, Hh not only regulates the survival and proliferation of tissue progenitor and stem populations but also is a critical moderator of MSC differentiation, involving tri-lineage and across embryonic layer differentiation of MSCs. This review summarizes the role of Hh signaling pathway in the differentiation of MSCs to mesodermal, endodermal, and ectodermal cells.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"29 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140836949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review 镰状细胞病的造血干细胞移植：多学科综述

IF 3.3 4区医学

Cell Transplantation Pub Date : 2024-04-29 DOI: 10.1177/09636897241246351

Tahereh Rostami, Soroush Rad, Mohammad Reza Rostami, Seied Amirhossein Mirhosseini, Hediyeh Alemi, Naghmeh Khavandgar, Ghasem Janbabai, Azadeh Kiumarsi, Amir Kasaeian, Seied Asadollah Mousavi

{"title":"Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review","authors":"Tahereh Rostami, Soroush Rad, Mohammad Reza Rostami, Seied Amirhossein Mirhosseini, Hediyeh Alemi, Naghmeh Khavandgar, Ghasem Janbabai, Azadeh Kiumarsi, Amir Kasaeian, Seied Asadollah Mousavi","doi":"10.1177/09636897241246351","DOIUrl":"https://doi.org/10.1177/09636897241246351","url":null,"abstract":"While exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) have been approved by the US Food and Drug Administration (FDA) as the first cell-based gene therapies for the treatment of patients 12 years of age and older with sickle cell disease (SCD), this treatment is not universally accessible. Allogeneic hematopoietic stem cell transplant (HSCT) has the potential to eradicate the symptoms of patients with SCD, but a significant obstacle in HSCT for SCD is the availability of suitable donors, particularly human leukocyte antigen (HLA)-matched related donors. Furthermore, individuals with SCD face an elevated risk of complications during stem cell transplantation due to SCD-related tissue damage, endothelial activation, and inflammation. Therefore, it is imperative to consider optimal conditioning regimens and investigate HSCT from alternative donors. This review encompasses information on the use of HSCT in patients with SCD, including the indications for HSCT, conditioning regimens, alternative donors, and posttransplant outcomes.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"18 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140836286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alpha-1 Antitrypsin Augmentation Therapy in Chronic Pancreatitis Patients Undergoing Total Pancreatectomy and Islet Autotransplantation: A Randomized, Controlled Study 接受全胰腺切除术和胰岛自体移植的慢性胰腺炎患者的 Alpha-1 抗胰蛋白酶增强疗法：随机对照研究

IF 3.3 4区医学

Cell Transplantation Pub Date : 2024-04-25 DOI: 10.1177/09636897241243014

Hongjun Wang, Wenyu Gou, Paul J. Nietert, Jason Hirsch, Jingjing Wang, Ahmed Allawi, Abd S. Mortadha, Kelsey Cook, Morgan Overstreet, Hua Wei, David Adams, William P. Lancaster, Katherine A. Morgan, Charlie Strange

{"title":"Alpha-1 Antitrypsin Augmentation Therapy in Chronic Pancreatitis Patients Undergoing Total Pancreatectomy and Islet Autotransplantation: A Randomized, Controlled Study","authors":"Hongjun Wang, Wenyu Gou, Paul J. Nietert, Jason Hirsch, Jingjing Wang, Ahmed Allawi, Abd S. Mortadha, Kelsey Cook, Morgan Overstreet, Hua Wei, David Adams, William P. Lancaster, Katherine A. Morgan, Charlie Strange","doi":"10.1177/09636897241243014","DOIUrl":"https://doi.org/10.1177/09636897241243014","url":null,"abstract":"Stress-induced islet graft loss during the peri-transplantation period reduces the efficacy of islet transplantation. In this prospective, randomized, double-blind clinical trial, we evaluated the safety and efficacy of 60 mg/kg human alpha-1 antitrypsin (AAT) or placebo infusion weekly for four doses beginning before surgery in chronic pancreatitis (CP) patients undergoing total pancreatectomy and islet autotransplantation (TP-IAT). Subjects were followed for 12 months post-TP-IAT. The dose of AAT was safe, as there was no difference in the types and severity of adverse events in participants from both groups. There were some biochemical signals of treatment effect with a higher oxygen consumption rate in AAT islets before transplantation and a lower serum C-peptide (an indicator of islet death) in the AAT group at 15 min after islet infusion. Findings per the statistical analysis plan using a modified intention to treat analysis showed no difference in the C-peptide area under the curve (AUC) following a mixed meal tolerance test at 12 months post-TP-IAT. There was no difference in the secondary and exploratory outcomes. Although AAT therapy did not show improvement in C-peptide AUC in this study, AAT therapy is safe in CP patients and there are experiences gained on optimal clinical trial design in this challenging disease.","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"22 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140803418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0